Evotec and Odyssey partner on autoimmune drug discovery

Evotec SE (NASDAQ: EVO) and Odyssey Therapeutics, Inc. (NASDAQ: ODTX) have entered an R&D collaboration to discover small molecule drug candidates for autoimmune and inflammatory diseases, according to a press release from Evotec.

Under the agreement, Odyssey will use Evotec's discovery platform, screening capabilities, and AI-enabled data science tools to identify and validate drug candidates across multiple disease targets. The collaboration pairs Odyssey's disease biology expertise with Evotec's compound libraries and high-throughput experimentation capabilities.

Evotec is eligible to receive milestone payments tied to the delivery of validated hit series for each target. Detailed financial terms were not disclosed.

Evotec Chief Scientific Officer Dr. Cord Dohrmann said: "Drug discovery increasingly depends on the ability to integrate deep disease biology with advanced experimental and computational approaches to drug discovery. This collaboration with Odyssey illustrates well Evotec's strategy in applying integrated discovery platform technologies to complex disease areas where new approaches are urgently needed."

You May Also Be Interested In

• OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
• MARA amends Texas power site purchase agreement, posts $100M deposit
• Hafnia files SEC prospectus for $300 million share offering